Zheng Quan Ri Bao Zhi Sheng
Search documents
国睿科技:公司生产经营一切正常,不存在应披露而未披露的事项
Zheng Quan Ri Bao Zhi Sheng· 2026-01-28 12:37
Core Viewpoint - Guorui Technology stated that its production and operations are normal, with no undisclosed matters, and is focused on enhancing technological innovation and product competitiveness to drive steady growth in operating performance [1] Group 1 - The company plans to implement two cash dividends in 2025 to enhance shareholder returns [1] - The stock price in the secondary market is influenced by various factors including economic environment, industry policies, market sentiment, and investor preferences, indicating complexity and volatility [1]
爱玛科技:公司始终高度重视全体股东利益,密切关注公司股价表现
Zheng Quan Ri Bao Zhi Sheng· 2026-01-28 12:37
Group 1 - The company emphasizes its commitment to the interests of all shareholders and closely monitors its stock price performance [1] - The stock price is influenced by multiple factors, and the company will continue to focus on its operations while enhancing its core competitiveness to reward investors [1]
山东钢铁:2025年年度业绩预告
Zheng Quan Ri Bao Zhi Sheng· 2026-01-28 12:37
(编辑 丛可心) 证券日报网讯 1月28日,山东钢铁发布公告称,公司预计2025年年度实现归属于母公司所有者的净利润 1.00亿元左右,与上年同期-28.91亿元(追溯调整后)相比,扭亏为盈,同比增利29.91亿元左右。 ...
迈威生物:公司负责大中华区和东南亚区域的开发及商业化
Zheng Quan Ri Bao Zhi Sheng· 2026-01-28 12:17
Core Viewpoint - The company Maiwei Biotech has developed a unique targeted monoclonal antibody, 9MW3011, for the treatment of Polycythemia Vera (PV), which is the only one of its kind globally [1] Group 1: Product Development - The 9MW3011 antibody has received external licensing for collaboration, with the company responsible for development and commercialization in Greater China and Southeast Asia [1] - The partner DISCMEDICINE, INC. is advancing the product in other regions and has obtained "Fast Track Designation" (FTD) and "Orphan Drug Designation" (ODD) from the FDA [1] Group 2: Clinical Trials - The Phase II clinical study targeting PV patients is set to complete its first dosing in the United States by September 2025, marking a significant milestone in the collaboration [1] - PV has been included in the second batch of rare disease catalog published by the National Health Commission in September 2023, indicating ongoing efforts to advance clinical enrollment in both China and the U.S. [1]
海天股份:关于控股股东部分股份质押及解除质押的公告
Zheng Quan Ri Bao Zhi Sheng· 2026-01-28 12:17
(编辑 王雪儿) 证券日报网讯 1月28日,海天股份发布公告称,公司近日接到控股股东四川海天投资有限责任公司函 告,获悉其所持有的本公司部分股份办理了质押及解除质押手续。本次质押4427万股,占其持股 16.53%,同时解除质押31,300,000股。 ...
天沃科技:预计2025年净利润同比增长45.60%至108.00%
Zheng Quan Ri Bao Zhi Sheng· 2026-01-28 12:12
证券日报网讯 1月28日,天沃科技发布公告称,公司2025年1月1日至2025年12月31日预计归属于上市公 司股东的净利润3,500.00万元至5,000.00万元,比上年同期增长45.60%至108.00%。 (编辑 王雪儿) ...
海利得:关于全资子公司完成注册登记的公告
Zheng Quan Ri Bao Zhi Sheng· 2026-01-28 12:12
Core Viewpoint - The company announced the establishment of a wholly-owned subsidiary to implement industrialization projects for spinning oil agents and LCP resin [1] Group 1 - The company will hold the seventh meeting of the ninth board of directors on January 24, 2026, to review the investment proposal [1] - The subsidiary will be set up in the Haining Economic Development Zone (Jianshan) Chemical New Materials Park [1] - The company has completed the registration of the wholly-owned subsidiary and obtained a business license [1]
蠡湖股份:预计2025年净利润同比增长98.12%至134.14%
Zheng Quan Ri Bao Zhi Sheng· 2026-01-28 12:12
Group 1 - The company, Lihus Co., announced an expected net profit attributable to shareholders of the listed company for 2025 to be between 110 million and 130 million yuan, representing a year-on-year growth of 98.12% to 134.14% [1]
金禾实业:关于全资子公司获得高新技术企业证书的公告
Zheng Quan Ri Bao Zhi Sheng· 2026-01-28 12:12
(编辑 王雪儿) 证券日报网讯 1月28日,金禾实业发布公告称,公司全资子公司安徽金禾合成材料研究院有限公司于近 日收到由安徽省工业和信息化厅、安徽省财政厅、国家税务总局安徽省税务局联合颁发的《高新技术企 业证书》,本次高新技术企业的认定是金禾研究院原高新技术企业证书有效期满后进行的重新认定。 ...
湖南白银:预计2025年净利润同比增长67.88%至126.78%
Zheng Quan Ri Bao Zhi Sheng· 2026-01-28 12:12
(编辑 王雪儿) 证券日报网讯 1月28日,湖南白银发布公告称,公司预计2025年度归属于上市公司股东的净利润为28, 500.00万元至38,500.00万元,比上年同期增长67.88%至126.78%。 ...